原始来源记录
决策级临床试验登记变更
Aura Biosciences: CoMpass Phase 3 顶线数据现指导为 Q4 2027
该公司更新了其 Phase 3 CoMpass 试验指导，现在预计 2026 年完成入组，15个月主要终点的顶线数据在 Q4 2027 年。这取代了之前的开放式时间表，并反映了由于需要记录的肿瘤生长和全球站点激活挑战而导致的入组速度低于预期。
关键事实
来源摘录
EX-99.1 2 aura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, MA – November 13, 2025 – Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business